Biphasic insulin aspart 30: literature review of adverse events associated with treatment

Clinical Therapeutics
Jaime DavidsonR Kawamori

Abstract

Biphasic insulin aspart 30 (BIAsp 30 [30% soluble, rapid-acting insulin aspart and 70% protamine-bound insulin aspart], NovoLog Mix 70/30, Novo Nordisk, Bagsvaerd, Denmark), a premixed insulin analogue, addresses both the prandial and basal aspects of glucose regulation when used once or twice daily in patients with type 1 or type 2 diabetes. It provides overall glycemic control similar to biphasic human insulin 30 (BHI 30, 30% human insulin and 70% neutral protamine Hagedorn [NPH] insulin) in patients with type 1 or type 2 diabetes. The aim of this review was to evaluate the safety profile associated with BIAsp 30 in patients with type 1 or type 2 diabetes versus that of comparator insulin products, including BHI 30 and biphasic insulin lispro 25 (Mix 25 [25% biphasic insulin lispro and 75% protaminated lispro], Humalog Mix 75/25, Eli Lilly and Company, Indianapolis, Indiana), together with the basal insulins, including NPH insulin and insulin glargine (Lantus, Sanofi-Aventis Pharmaceuticals, Paris, France). Data from human clinical studies published in peer-reviewed journals or as conference proceedings that reported safety results in patients with type 1 or type 2 diabetes who were treated with BIAsp 30 versus comparator ins...Continue Reading

References

Nov 12, 1992·The New England Journal of Medicine·H Yki-JärvinenP Seppälä
Nov 1, 1991·Diabetic Medicine : a Journal of the British Diabetic Association·A VølundJ Schlichtkrull
May 1, 1995·Diabetic Medicine : a Journal of the British Diabetic Association·L Heinemann
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Oct 8, 1999·Diabetic Medicine : a Journal of the British Diabetic Association
Jun 15, 2000·European Journal of Clinical Pharmacology·H E Turner, D R Matthews
Sep 29, 2000·European Journal of Clinical Pharmacology·L V JacobsenA Riis
Feb 7, 2002·Expert Opinion on Pharmacotherapy·Simon HellerAnders Lindholm
May 25, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·B O BoehmA Lindholm
Jun 16, 2004·Circulation·Katherine EspositoUNKNOWN Campanian Postprandial Hyperglycemia Study Group
Aug 17, 2004·The Medical Clinics of North America·Trent Davis, Steven V Edelman
Sep 15, 2004·Diabetes Research and Clinical Practice·Mark L WarrenElsie Allen
Jan 26, 2005·European Journal of Internal Medicine·Bernhard O BoehmPhilip D Home
Jan 29, 2005·Diabetes Care·Philip RaskinUNKNOWN INITIATE Study Group

❮ Previous
Next ❯

Citations

Jun 23, 2009·Expert Opinion on Drug Safety·Joanna Mitri, Osama Hamdy
Apr 1, 2008·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Santiago Durán GarcíaAlfonso Pumar López
Jan 31, 2008·Diabetes/metabolism Research and Reviews·Patrick J Boyle, John Zrebiec
Oct 19, 2016·PharmacoEconomics·Asrul Akmal ShafieNathorn Chaiyakunapruk
Nov 26, 2009·Expert Opinion on Pharmacotherapy·Domenico Cucinotta, Giuseppina T Russo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.